Aptima® Herpes Simplex Viruses 1 & 2 Assay

Expand your testing capability with qualitative detection and differentiation of Herpes simplex viruses (HSV) 1 and 2.

Information for Healthcare Professionals

Assay box in blur background

    Overview

    Documents

    Identify a Common Viral Threat

    A Nucleic Acid Amplification Test (NAAT) is the preferred testing method for genital herpes diagnosis.1,2 Distinguishing between HSV 1 and 2 is recommended for all patients with first-episode genital herpes.3

    Clarity & Confidence in Every Diagnosis

    The Aptima HSV 1 & 2 Assay delivers high performance and reliable results from skin lesion swabs in the anogenital or oral region.

    Molecular HSV Testing Matters

    A molecular NAAT is 3-5 times more sensitive than a culture.4

    An Important Distinction

    The assay detects and differentiates HSV 1 and 2, as each type has a unique presentation that requires targeted treatment and management.3

    Seamless Testing Integration

    The Aptima HSV 1 &2 assay is an ideal complement to the growing list of assays on the fully automated Panther® System, providing customers with increased efficiency through platform consolidation.

    Technician walking through Panther systems in a lab setting

    Simplify & Scale the Future of Diagnostics

    The Aptima HSV 1 & 2 Assay is part of the Hologic Molecular Scalable Solution, a portfolio combining a broad, high-performing assay menu with high-throughput automation. Designed to flexibly scale to meet your needs, from a single patient result to population level screening.

    Proven Performance

    Accurate detection and differentiation of HSV1 and HSV2.1

    High sensitivity and specificity

    in Anogenital and Oral lesions

    Robust assay performance

    in the presence of anti-viral medication

    Aptima® specimen collection

    in Viral Transport Media (VTM) and Multitest Swab Specimen Collection Kit 

    One Sample, Multiple STI Results

    Clinically relevant sample type options make the Aptima HSV 1 & 2 Assay easy to order as a standalone or in combination with other assays from the automated Hologic STI Solution. Browse relevant collection devices below.

    Scan of Viruses

    More than 3.7 Billion Infected Globally5

    Each type of HSV 1 or 2 has a unique presentation that requires targeted treatment.4 Diagnosing and distinguishing between HSV 1 and 2 is important because:

    • Patients can prevent transmission to neonates and among sex partners5
    • Providers can guide patient treatment and daily management6
    • Patients with HSV 2 are 2-3 times higher risk for HIV-1 transmission and acquisition6-9

    Insights

    Healthcare provider looking at scan images on monitor display

    FDA Market Authorisation for Genius™ Digital Diagnostics System

    Cervical screening infographics

    Discover the Future of Cervical Cancer Screening

    PCR tests in a rack held by a hand wearing gloves.

    The Molecular Diagnostics Revolution and Its Impact on Personalised Care

      1. Aptima Herpes Simplex Viruses 1 & 2 Assay [package insert]. AW-15346-001 Rev 005. San Diego, CA: Hologic, Inc., 2023.
      2. WHO Global Health Sector Strategy on Sexually Transmitted Infections 2016–2021. Accessed August 16, 2022. https://apps.who.int/iris/bitstream/handle/10665/246296/WHO-RHR-16.09-eng.pdf?sequence=1.
      3. Patel R, Kennedy O, Clarke E, et al. 2017 European guidelines for the management of genital herpes. Int J STD AIDS. 2017Dec;28(14):1366-1379
      4. Hook EW. A new look at genital herpes: the critical role of the laboratory in diagnosis and management. MLO Med Lab Obs. 2012 Jul;44(7):8, 10, 12
      5. World Health Organization. Herpes simplex virus. http://www.who.int/mediacentre/factsheets/fs400/en/. Reviewed January 2017. Accessed January 28, 2020.
      6. Freeman E, Weiss H, Glynn J, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20(1):73-83.
      7. Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 se-rostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis. 2009;199(7):958-64.
      8. Glynn J, Caraël M, Auvert B, et al. Why do young women have a much higher prevalence of HIV than young men? A study in Kisumu, Kenya and Ndola, Zambia. AIDS. 2001 Aug;15 ( Suppl 4):S51–60.
      9. Ward H, and Rönn M. The contribution of STIs to the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):305-10.doi:10.1097/COH.0b013e32833a884.

      Safety Data Sheets

      Package Inserts

      1434

      Hologic BV, Da Vincilaan 5, 1930 Zaventem, Belgium.

      Notified Body number wherever applicable